VialGLP-3R 10 mg cartridge
Triple-agonist weight research
Investigated for GLP-1, GIP and glucagon receptor signaling.
$139 when in stock
Pen cartridge sold out · the vial is in stock
Shop the vial · from $119- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Compare. Side by side, from the research.
About GLP-3R
GLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.
How it works
- Triple Agonism
- Studied at three distinct metabolic receptors, the glucagon component being what separates it from dual agonists.
- Energy Expenditure
- Explored for whether glucagon receptor activity contributes an expenditure effect alongside appetite signaling.
What you need
- Reusable Metal Pen
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Single cartridge for the reusable CoreX pen
- Strength
- 10 mg per cartridge
- Storage
- Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
- Route in research
- Subcutaneous
- Target
- GLP-1R / GIPR / GCGR
- SKU
- RT10SC
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Late clinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Late clinicalGLP-3R has progressed through phase 2 trials in obesity and metabolic dysfunction-associated steatotic liver disease and has been evaluated in a published randomized phase 3 trial in type 2 diabetes, with further registrational trials described.
What research examines
- Body weight reduction in adults with obesity
- Glycemic control in type 2 diabetes
- Liver fat in metabolic dysfunction-associated steatotic liver disease
- Obstructive sleep apnea and knee osteoarthritis in registrational trial designs
- Glucagon receptor contribution to energy expenditure
Reported in studies
- Safety has been assessed in randomized phase 2 and phase 3 trials, though specific adverse events are not summarized on this page
- Long-term human safety data remain limited while registrational trials continue
- No regulatory approval for any indication has been reported
Published research protocols
1 mg, 1/week, am fasted
Research protocols have used 500–4,000 mcg per administration, once weekly (morning, fasted), stepping up from 1 mg to 4 mg by week 9. Reported cycle: continuous until target weight loss; long-term non-weight-loss model: 1mg weekly.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Measure with the calculatorCoreX AI
Ask about GLP-3R
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with GLP-3R
Researched for weight & body composition.
Vial
Vial
Vial
FAQ
Questions, answered
GLP-3R is a research peptide studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three receptors affects metabolic regulation differently from dual or single agonists. It has been evaluated in randomized clinical trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease, and is sold by CoreX for laboratory research use only.
Research investigates GLP-3R across three receptors. GLP-1 and GIP receptor activity is associated with glucose-dependent insulin signaling and satiety, while glucagon receptor activity is associated with energy expenditure. Studies explore whether the glucagon component adds an expenditure effect alongside appetite signaling, which is the main feature distinguishing it from dual GLP-1/GIP agonists.
Published work includes a phase 2 randomized trial in obesity, a phase 2a randomized trial in metabolic dysfunction-associated steatotic liver disease, and a double-blind randomized phase 3 trial in people with type 2 diabetes and inadequate glycemic control on diet and exercise. Registrational trials have also been designed to examine obesity, obstructive sleep apnea, and knee osteoarthritis.
Safety outcomes were assessed in the phase 2 and phase 3 randomized trials, but the specific adverse event profile is not summarized on this page. Long-term human safety data remain limited, and larger registrational trials are ongoing. No regulatory approval has been reported, and GLP-3R supplied by CoreX is intended for laboratory research use only.
Research protocols have used 500 to 4,000 mcg per administration by subcutaneous route, once weekly (morning, fasted), stepping up from 1 mg to 4 mg by week 9. The reported cycle continued until target weight loss, and a long-term non-weight-loss model used 1 mg weekly. Each CoreX order ships with a protocol guide for laboratory reference.
You may also like
Vial · Pen
Vial
Vial
Vial
Vial · Pen
Vial